Page 1 | Search Results | Blood | American Society of Hematology

Skip to Main Content

Skip Nav Destination

1-4 of 4

Sort by

Sort Order Select

Journal Articles

BGB-11417-203, an Ongoing, Phase 2 Study of Sonrotoclax (BGB-11417), a Next-Generation BCL2 Inhibitor, in Patients With Waldenström Macroglobulinemia

Hui-Peng Lee, Stephen S. Opat, John Hrom, David Kliman, Paula Marlton, Peng Liu, Chenmu Du, Amber Lussier, Jun Zhang, Haiyi Guo, Steven P. Treon

Blood (2024) 144 (Supplement 1): 1661.1.

https://doi.org/10.1182/blood-2024-198728

Published: 2024

Journal Articles

Real-World Evidence (RWE) Studies Supported Hematologic Oncology United States Food and Drug Administration (US FDA) Approval: What Do They Look like?

Binglin Yue, Adam Greenbaum, Shaohui Sun, Enda Zhu, Shicheng Weng, Chenmu Du, Xiaojuan Zhang, Shanmei Liao

Blood (2022) 140 (Supplement 1): 13208–13209.

https://doi.org/10.1182/blood-2022-166800

Published: 2022

Journal Articles

Preliminary Safety of a Bcl-2 Inhibitor, Bgb-11417, in Patients with Relapsed/Refractory Multiple Myeloma Harboring t(11,14): A Non-Randomized, Open-Label, Phase 1b/2 Study

Hang Quach, Rajeev Rajagopal, Andrew Spencer, Michael Low, Dickran Kazandjian, Rocco Crescenzo, Chenmu Du, Sheel Patel, Vaibhav Mundra, Huan Cheng, Binod Dhakal

Blood (2022) 140 (Supplement 1): 7269–7271.

https://doi.org/10.1182/blood-2022-169666

Published: 2022

Journal Articles

Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with WaldenstrC6m Macroglobulinemia from a Phase 2 Trial

Gang An, MD PhD, Daobin Zhou, MD PhD, Weili Zhao, MD PhD, Keshu Zhou, MD PhD, Jianyong Li, MD PhD, Jianfeng Zhou, MD PhD, Liping Xie, MD PhD, Jie Jin, MD PhD, Liye Zhong, MD PhD, Lingzhi Yan, MD PhD, Haiyi Guo, MD, Chenmu Du, MD, Jane Huang, MD, William Novotny, MD, Jinhua Zhong, PhD, Lugui Qiu, MD

Blood (2020) 136 (Supplement 1): 42–43.

https://doi.org/10.1182/blood-2020-136783

Published: 2020